# Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

> **NCT04639271** · PHASE2 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Pyrotinib Plus And
- **DRUG:** Trastuzumab
- **DRUG:** Abraxane

## Key facts

- **NCT ID:** NCT04639271
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04639271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04639271, "Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04639271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*